Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06931275 · ClinicalTrials.gov registry record · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
A NA study of Diabetes Mellitus, Type 1, sponsored by T1D Exchange, United States.
- Recruiting
- Registry status
- NA
- Development phase
- 1,178
- Enrollment target
- 2
- Study locations
NCT06931275: Recruiting NA study of Diabetes Mellitus, Type 1, sponsored by T1D Exchange, United States.
NCT06931275 is a NA study of Diabetes Mellitus, Type 1 that is actively recruiting participants, run by T1D Exchange, United States. The registered enrollment target is 1,178 participants, roughly in line with the 1,256-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06931275, a NA study of Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by T1D Exchange, United States.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,178 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overall goal of the study is to create a standardized, stakeholder-informed system within EMRs, that will enable an equitable and regular prescription and documentation of advanced diabetes technologies. This will reduce racial disparities and generate an understanding of the reasons behind prescription decisions. The study will highlight the development and implementation an EMR-based Best Practice Advisory (BPA). The study will answer whether the EMR-based BPA can effectively reduce disparities. Additionally, it will explore why providers may not prescribe advanced diabetes technologies. Patients will also be surveyed to understand their perspectives on developing the EMR-based BPA.
Primary Outcome
Defined as positive for an individual if: • MDI/smartpen + no CGM begins using CGM * MDI/smartpen + CGM begins using insulin pump * Insulin pump + no CGM begins using CGM * Insulin pump + CGM (without AID) begins using AID
Conditions Studied
Interventions
- OTHER EMR-based BPA model
- BEHAVIORAL Placebo (EMR-based without BPA model)
Study Locations (2)
Massachusetts
- T1D Exchange - Boston
- T1D Exchange - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,178 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2027-07-30 |
| Phase | NA |
What NCT06931275 shows while recruiting
NCT06931275 is an interventional study that assigns participants to a tested intervention. Its 1,178 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,256-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which EMR-based BPA model is the first listed.
NCT06931275 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06931275 about?
NCT06931275 is a clinical study titled "Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes". The overall goal of the study is to create a standardized, stakeholder-informed system within EMRs, that will enable an equitable and regular prescription and documentation of advanced diabetes technologies. This will reduce racial disparities and generate an understanding of the reasons behind pres...
What is the current status of trial NCT06931275?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,178 participants. The study started on 2024-08-13. Estimated completion is 2027-07-30.
What conditions does trial NCT06931275 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT06931275?
The interventions under investigation include: EMR-based BPA model (OTHER), Placebo (EMR-based without BPA model) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06931275?
This trial is sponsored by T1D Exchange, United States, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06931275 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06931275's enrollment target sits among peer trials
1,178 6th of 118 higher than 113 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
-
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
RECRUITING · NA
-
National Institute of Diabetes and Digestive Kidney Diseases* Share Plus: Continuous Glucose Monitoring with Data Sharing in Older Adults with Type 1 Diabetes* and Their Care Partners to Improve Time in Range and Reduce Diabetes Distress.
RECRUITING · NA
-
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
RECRUITING · NA
-
Closed Loop and Education for Hypoglycemia Awareness Restoration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06133322 · 1,176 participants · NA
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- NCT04275557 · 1,174 participants
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI